Semler Matthew W, Wanderer Jonathan P, Ehrenfeld Jesse M, Stollings Joanna L, Self Wesley H, Siew Edward D, Wang Li, Byrne Daniel W, Shaw Andrew D, Bernard Gordon R, Rice Todd W
1 Division of Allergy, Pulmonary, and Critical Care Medicine.
2 Department of Anesthesiology.
Am J Respir Crit Care Med. 2017 May 15;195(10):1362-1372. doi: 10.1164/rccm.201607-1345OC.
Saline is the intravenous fluid most commonly administered to critically ill adults, but it may be associated with acute kidney injury and death. Whether use of balanced crystalloids rather than saline affects patient outcomes remains unknown.
To pilot a cluster-randomized, multiple-crossover trial using software tools within the electronic health record to compare saline to balanced crystalloids.
This was a cluster-randomized, multiple-crossover trial among 974 adults admitted to a tertiary medical intensive care unit from February 3, 2015 to May 31, 2015. The intravenous crystalloid used in the unit alternated monthly between saline (0.9% sodium chloride) and balanced crystalloids (lactated Ringer's solution or Plasma-Lyte A). Enrollment, fluid delivery, and data collection were performed using software tools within the electronic health record. The primary outcome was the difference between study groups in the proportion of isotonic crystalloid administered that was saline. The secondary outcome was major adverse kidney events within 30 days (MAKE30), a composite of death, dialysis, or persistent renal dysfunction.
Patients assigned to saline (n = 454) and balanced crystalloids (n = 520) were similar at baseline and received similar volumes of crystalloid by 30 days (median [interquartile range]: 1,424 ml [500-3,377] vs. 1,617 ml [500-3,628]; P = 0.40). Saline made up a larger proportion of the isotonic crystalloid given in the saline group than in the balanced crystalloid group (91% vs. 21%; P < 0.001). MAKE30 did not differ between groups (24.7% vs. 24.6%; P = 0.98).
An electronic health record-embedded, cluster-randomized, multiple-crossover trial comparing saline with balanced crystalloids can produce well-balanced study groups and separation in crystalloid receipt. Clinical trial registered with www.clinicaltrials.gov (NCT 02345486).
生理盐水是重症成年患者最常用的静脉输液,但它可能与急性肾损伤和死亡有关。使用平衡晶体液而非生理盐水是否会影响患者预后尚不清楚。
开展一项整群随机、多次交叉试验,利用电子健康记录中的软件工具比较生理盐水和平衡晶体液。
这是一项整群随机、多次交叉试验,纳入了2015年2月3日至2015年5月31日入住三级医疗重症监护病房的974名成年患者。该病房使用的静脉晶体液每月在生理盐水(0.9%氯化钠)和平衡晶体液(乳酸林格氏液或Plasma-Lyte A)之间交替。使用电子健康记录中的软件工具进行入组、液体输注和数据收集。主要结局是研究组之间给予的等渗晶体液中生理盐水所占比例的差异。次要结局是30天内的主要不良肾脏事件(MAKE30),定义为死亡、透析或持续性肾功能不全的复合事件。
分配至生理盐水组(n = 454)和平衡晶体液组(n = 520)的患者在基线时相似,到30天时接受的晶体液量相似(中位数[四分位间距]:1424 ml[500 - 3377] vs. 1617 ml[500 - 3628];P = 0.40)。生理盐水组给予的等渗晶体液中生理盐水所占比例高于平衡晶体液组(91% vs. 21%;P < 0.001)。两组间MAKE30无差异(24.7% vs. 24.6%;P = 0.98)。
一项在电子健康记录中嵌入的、整群随机、多次交叉试验,比较生理盐水和平衡晶体液,可产生平衡良好的研究组并区分晶体液的使用情况。该临床试验已在www.clinicaltrials.gov注册(NCT 02345486)。